Massachusetts Institute of Technology
http://web.mit.edu/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Massachusetts Institute of Technology
The Runners And Riders In Hidradenitis Suppurativa
Despite its Phase III blow-up, Acelyrin is continuing to back izokibep in the skin disease. But other developers are trying immune agents old and new in what could turn into a billion-dollar market.
Biotech IPOs Get Bigger, But Not Necessarily Better
The first $1bn quarter since 2021 suggests that biotech’s IPO window is opening once more. But times remain tough, and many recently listed groups have seen their valuations fall.
Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
Company Information
- Industry
- Academic and Research Institutions
- Other Names / Subsidiaries
-
- MIT
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice